NO174964C - Analogifremgangsmåte for fremstilling av aromatiske inhibitorer for steroid 5- - Google Patents

Analogifremgangsmåte for fremstilling av aromatiske inhibitorer for steroid 5-

Info

Publication number
NO174964C
NO174964C NO894065A NO894065A NO174964C NO 174964 C NO174964 C NO 174964C NO 894065 A NO894065 A NO 894065A NO 894065 A NO894065 A NO 894065A NO 174964 C NO174964 C NO 174964C
Authority
NO
Norway
Prior art keywords
beta
alpha
preparation
steroid
analogous process
Prior art date
Application number
NO894065A
Other languages
English (en)
Other versions
NO894065D0 (no
NO894065L (no
NO174964B (no
Inventor
Dennis Alan Holt
Mark Alan Levy
Brian Walter Metcalf
Original Assignee
Smithkline Beckman Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beckman Corp filed Critical Smithkline Beckman Corp
Publication of NO894065D0 publication Critical patent/NO894065D0/no
Publication of NO894065L publication Critical patent/NO894065L/no
Publication of NO174964B publication Critical patent/NO174964B/no
Publication of NO174964C publication Critical patent/NO174964C/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
    • C07J13/005—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 16 (17)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0059—Estrane derivatives substituted in position 17 by a keto group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
    • C07J13/007—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 17 (20)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
    • C07J3/005—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom the carbon atom being part of a carboxylic function
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0072—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the A ring of the steroid being aromatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0094—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing nitrile radicals, including thiocyanide radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/008—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
    • C07J7/0095—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21 carbon in position 21 is part of carboxylic group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NO894065A 1988-05-25 1989-10-11 Analogifremgangsmåte for fremstilling av aromatiske inhibitorer for steroid 5- NO174964C (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US19853488A 1988-05-25 1988-05-25

Publications (4)

Publication Number Publication Date
NO894065D0 NO894065D0 (no) 1989-10-11
NO894065L NO894065L (no) 1991-04-12
NO174964B NO174964B (no) 1994-05-02
NO174964C true NO174964C (no) 1994-08-10

Family

ID=22733779

Family Applications (1)

Application Number Title Priority Date Filing Date
NO894065A NO174964C (no) 1988-05-25 1989-10-11 Analogifremgangsmåte for fremstilling av aromatiske inhibitorer for steroid 5-

Country Status (16)

Country Link
EP (1) EP0343954B1 (no)
JP (1) JP2675418B2 (no)
AT (1) ATE114665T1 (no)
AU (1) AU627466B2 (no)
CA (1) CA1331457C (no)
DE (1) DE68919537T2 (no)
DK (2) DK168295B1 (no)
ES (1) ES2065378T3 (no)
GR (1) GR3015135T3 (no)
HK (1) HK1006461A1 (no)
IE (1) IE68858B1 (no)
IL (1) IL91968A (no)
NO (1) NO174964C (no)
PT (1) PT90656B (no)
WO (1) WO1989011282A1 (no)
ZA (1) ZA893971B (no)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5138063A (en) * 1984-02-27 1992-08-11 Merck & Co., Inc. 17β-methoxycarbonyl-4-aza-androsten-1-en-3-ones
US5571817A (en) * 1984-02-27 1996-11-05 Merck & Co., Inc. Methods of treating androgenic alopecia with finasteride [17β-N-mono-substituted-carbamoyl-4-aza-5-α-androst-1-en-ones]
US5162332A (en) * 1990-06-20 1992-11-10 Merck & Co., Inc. Selected 17 β-polyaroyl-4-aza-5 α-androst-1-en-3-ones as steroidal reductase inhibitors
US5061802A (en) * 1990-06-20 1991-10-29 Merck & Co. Inc. 17β-aminobenzoyl-4-aza-5α-androst-1-en-3-ones as benign prostatic hypertrophy agents
US5098908A (en) * 1990-06-20 1992-03-24 Merck & Co., Inc. 17β-hydroxybenzoyl-4-aza-5α-androst-1-en-3-ones as testosterone reductase inhibitors
US5151430A (en) * 1990-06-20 1992-09-29 Merck & Co., Inc. Specific 17β-thiobenzoyl-4-aza-5α-androst-1-en-3-ones as antiandrogen agents
US5091380A (en) * 1990-06-28 1992-02-25 Merck & Co., Inc. N-monosubstituted adamantyl/norbornanyl 17β-carbamides of 3-carboxy-androst-3,5-dienes as testosterone 5α-reductase inhibitors
NZ241979A (en) * 1991-03-20 1996-01-26 Merck & Co Inc Treatment of benign prostatic hyperplasia using 5alpha-reductase inhibitor and an alpha1-adrenergic recepter blocker
JPH07506363A (ja) * 1992-04-30 1995-07-13 スミスクライン・ビーチャム・コーポレイション １７αおよび１７β−置換のエストラ−１，３，５（１０）−トリエン−３−カルボン酸
WO1993023040A1 (en) * 1992-05-20 1993-11-25 Merck & Co., Inc. 17-ethers and thioethers of 4-aza-steroids
EP0649306B1 (en) * 1992-05-20 2001-01-10 Merck & Co. Inc. Ester derivatives of 4-aza-steroids
US5620986A (en) * 1992-05-20 1997-04-15 Merck & Co., Inc. 17 urea, thiourea, thiocarbamyl and carbamyl4-azasteroid 5-reductase inhibitors useful in the prevention and treatment of hyperandrogenic disorders
WO1993023038A1 (en) * 1992-05-20 1993-11-25 Merck & Co., Inc. 17-AMINO SUBSTITUTED 4-AZASTEROID 5α-REDUCTASE INHIBITORS
US5237064A (en) * 1992-05-20 1993-08-17 Merck & Co., Inc. Process for producing 7β-substituted-aza-5αandrostan-3-ones
WO1993023419A1 (en) * 1992-05-20 1993-11-25 Merck & Co., Inc. NEW 7β-SUBSTITUTED-4-AZA-5α-CHOLESTAN-ONES AS 5α-REDUCTASE INHIBITORS
US5324734A (en) * 1992-09-15 1994-06-28 Merck & Co., Inc. Oxidization metabolites of 5-α-23-methyl-4-aza-21-nor-chol-1-ene-3, 20-dione
US5278159A (en) * 1992-10-06 1994-01-11 Merck & Co., Inc. Aryl ester derivatives of 3-oxo-4-aza-androstane 17-β-carboxylates as 5-α-reductase inhibitors
US5683995A (en) * 1992-11-18 1997-11-04 Smithkline Beecham Corporation 17 substituted acyl-3-carboxy 3,5-diene steroidals as α-reductase inhibitors
US5641765A (en) * 1992-11-18 1997-06-24 Smithkline Beecham Corporation 17-αand 17-βsubstituted acyl-3-carboxy-3,5-dienes and use in inhibiting 5-α-reductase
US5359071A (en) * 1993-03-12 1994-10-25 Merck & Co., Inc. 15-substituted 4-azasteroids
WO1994021614A1 (en) * 1993-03-24 1994-09-29 Merck & Co., Inc. SUBSTITUTED 3-PHENANTHRIDINONE DERIVATIVES AS 5α-REDUCTASE INHIBITORS
ATE158301T1 (de) * 1993-06-28 1997-10-15 Merck & Co Inc 4-aza-pregnan-5-alpha-reductase isozym 1 inhibitoren
TW369521B (en) * 1993-09-17 1999-09-11 Smithkline Beecham Corp Androstenone derivative
US5430157A (en) * 1993-12-13 1995-07-04 Eli Lilly And Company Reduced phenanthrenes
US5541322A (en) * 1994-10-14 1996-07-30 Glaxo Wellcome Inc. Synthesis of 6-azaandrostenones
US5595996A (en) * 1994-10-25 1997-01-21 Merck & Co., Inc. 7-substituted 4-aza cholanic acid derivatives and their use
GB201102913D0 (en) 2011-02-18 2011-04-06 Univ Birmingham Novel therapeutic

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1107664B (de) * 1959-11-05 1961-05-31 Schering Ag Verfahren zur Herstellung neuer in 3-Stellung substituierter OEstratriene
US3622670A (en) * 1969-08-22 1971-11-23 American Home Prod Method of inducing ovulation
US4185101A (en) * 1977-08-11 1980-01-22 Schering Corporation 1,3,5(10),6,8-19-Nor-pregnapentaenes, their use as anti-psoriatic agents, and pharmaceutical formulations useful therefor
US4191759A (en) * 1978-04-13 1980-03-04 Merck & Co., Inc. N-substituted-17β-carbamoylandrost-4-en-3-one 5α reductase inhibitors
US4340602A (en) * 1978-10-18 1982-07-20 Wayne State University Compositions inhibiting estrogen sulfotransferase activity
US4910226A (en) * 1987-04-29 1990-03-20 Smithkline Beckman Corporation Steroid 5-alpha-reductase inhibitors

Also Published As

Publication number Publication date
ES2065378T3 (es) 1995-02-16
HK1006461A1 (en) 1999-02-26
PT90656B (pt) 1994-10-31
EP0343954A3 (en) 1990-05-16
JP2675418B2 (ja) 1997-11-12
AU627466B2 (en) 1992-08-27
GR3015135T3 (en) 1995-05-31
AU3748789A (en) 1989-12-12
NO894065D0 (no) 1989-10-11
DK169787B1 (da) 1995-02-27
NO894065L (no) 1991-04-12
IE891732L (en) 1989-11-25
ATE114665T1 (de) 1994-12-15
EP0343954A2 (en) 1989-11-29
DK168295B1 (da) 1994-03-07
IL91968A (en) 1994-10-21
DK279790A (da) 1990-11-23
DK130393D0 (da) 1993-11-19
JPH03504498A (ja) 1991-10-03
CA1331457C (en) 1994-08-16
IE68858B1 (en) 1996-07-24
DK279790D0 (da) 1990-11-23
DE68919537T2 (de) 1995-05-11
WO1989011282A1 (en) 1989-11-30
PT90656A (pt) 1989-11-30
EP0343954B1 (en) 1994-11-30
NO174964B (no) 1994-05-02
DK130393A (da) 1993-11-19
DE68919537D1 (de) 1995-01-12
ZA893971B (en) 1990-05-30

Similar Documents

Publication Publication Date Title
NO174964C (no) Analogifremgangsmåte for fremstilling av aromatiske inhibitorer for steroid 5-
ATE118505T1 (de) Phosphinsäure-derivate von aromatischen steroiden als 5-alpha reduktase-inhibitoren.
ATE114666T1 (de) Phosphonsäure-derivate von aromatischen steroiden als 5-alpha-reduktase-inhibitoren.
ZA899669B (en) Sulfonic acid substituted aromatic steroids as inhibitors of steroid 5-alpha-reductase
DK496089D0 (da) Biologisk aktive phenylalkansyreforbindelser og fremgangsmaade til fremstilling deraf
SE8804036D0 (sv) New use of 11,28-dioxa-4-azatricyclo(22.3.1.0?724,9 )octacos-18-ene derivatives and pharmaceutical compositions containing them
DE68914793T2 (de) Chinazolinon-Derivate.
DK245888D0 (da) 4-aminoquinolinderivater
DE68909107T2 (de) 4-Amino-3-acylchinolin-Derivate und ihre Verwendung als Inhibitoren der Magensekretion.
ES538847A0 (es) Un derivado de fenilserina
PT85501A (en) Process for the preparation of novel phenoxyacetic acid derivatives and of pharmaceutical compositions containing the same
AU4730889A (en) Novel carboximidamide derivatives
DE3884878D1 (de) Uricosuretische Zusammensetzung.
GB1471546A (en) 1-acyl-4-substituted alkyl-piperazine or homopiperazine derivatives nad process for preparation thereof